India High Court Blocks Contentious Zandu Annual Meeting
This article was originally published in PharmAsia News
India's Bombay High Court blocked the annual general meeting of Zandu Pharmaceutical Works, with the assent of two parties fighting over the firm. Chairman Y.P. Trivedi, also an independent director of Zandu, said the cancellation of the meeting would give the opposing parties, Emami and the Parikhs, time to resolve their differences. The agenda of the meeting had included appointment of five nominees by the Parikhs to the company board, a move opposed by Emami. (Click here for more
You may also be interested in...
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.
AdvaMed CEO Scott Whitaker shared a letter he sent to member companies voicing support for the ongoing protests around the US against police brutality that were sparked after the killing of George Floyd. “While we continue our single-minded pursuit of medical breakthroughs to treat and cure disease, we must also have a single-minded focus on eradicating the disease of racism in this country and around the world,” Whitaker wrote.